Cargando…
Compared efficacy and tolerance of the neuromuscular blockade induced by brand-name (Nimbex®) and generic (Cisatrex®) of cisatracurium in mechanically ventilated critically ill patients: a crossover double-blind randomized study
INTRODUCTION: use of generic drugs is common. However, there is still concern among patients and physicians that brand name drugs are more efficient. The aim of the study was to compare efficacy and tolerance between two forms of cisatracurium: brand name versus generic name. METHODS: it´s a crossov...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The African Field Epidemiology Network
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934181/ https://www.ncbi.nlm.nih.gov/pubmed/33738034 http://dx.doi.org/10.11604/pamj.2020.37.346.24986 |
_version_ | 1783660769906262016 |
---|---|
author | Fraj, Nesrine Meddeb, Khaoula Azouzi, Abdelbaki Romdhani, Sana Saad, Helmi Ben Boussarsar, Mohamed |
author_facet | Fraj, Nesrine Meddeb, Khaoula Azouzi, Abdelbaki Romdhani, Sana Saad, Helmi Ben Boussarsar, Mohamed |
author_sort | Fraj, Nesrine |
collection | PubMed |
description | INTRODUCTION: use of generic drugs is common. However, there is still concern among patients and physicians that brand name drugs are more efficient. The aim of the study was to compare efficacy and tolerance between two forms of cisatracurium: brand name versus generic name. METHODS: it´s a crossover, randomized, double-blind physiological trial. Patients admitted for hypoxemic acute respiratory failure with PaO2/FIO2 < 200mmHg despite optimized ventilation and sedation thus requiring non-depolarizing neuromuscular blocking agents (NMBAs), were enrolled. Patients received consecutively, in a random order, cisatracurium brand name (Nimbex®) and generic (Cisatrex®) over two-hour period separated by one-hour washout period. Neuromuscular function was monitored by a calibrated train-of-four (TOF) stimulation device. Paralysis time delay to reach TOF of 2/4, recovery kinetics and tolerance were monitored. The number needed to demonstrate a significant difference in time delays to reach a TOF of 2/4 between the two forms of cisatracurium was estimated at 22 patients. RESULTS: twenty-two patients were included. Eight (36.4%) had acute respiratory distress syndrome; 8(36.4%), acute exacerbation of chronic obstructive pulmonary disease and 3(13.6%), status asthmaticus. Median [IQR] SAPS II at admission, 28.5 [22, 41]. PaO2/FIO2, 121 [81, 156] mmHg. Paralysis time delays were respectively, 80 [50, 112] vs. 87 [65, 115] minutes, in Nimbex® group and Cisatrex® group; (p=0.579). Within the recovery period, the between two-studied drugs´ difference in TOF was at 0.25±0.96; p=0.64. There were no significant hemodynamic differences. CONCLUSION: the present study revealed no significant differences in efficacy nor in tolerance between cisatracurium brand name Nimbex® and generic name Cisatrex® in hypoxemic ventilated patients. |
format | Online Article Text |
id | pubmed-7934181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The African Field Epidemiology Network |
record_format | MEDLINE/PubMed |
spelling | pubmed-79341812021-03-17 Compared efficacy and tolerance of the neuromuscular blockade induced by brand-name (Nimbex®) and generic (Cisatrex®) of cisatracurium in mechanically ventilated critically ill patients: a crossover double-blind randomized study Fraj, Nesrine Meddeb, Khaoula Azouzi, Abdelbaki Romdhani, Sana Saad, Helmi Ben Boussarsar, Mohamed Pan Afr Med J Research INTRODUCTION: use of generic drugs is common. However, there is still concern among patients and physicians that brand name drugs are more efficient. The aim of the study was to compare efficacy and tolerance between two forms of cisatracurium: brand name versus generic name. METHODS: it´s a crossover, randomized, double-blind physiological trial. Patients admitted for hypoxemic acute respiratory failure with PaO2/FIO2 < 200mmHg despite optimized ventilation and sedation thus requiring non-depolarizing neuromuscular blocking agents (NMBAs), were enrolled. Patients received consecutively, in a random order, cisatracurium brand name (Nimbex®) and generic (Cisatrex®) over two-hour period separated by one-hour washout period. Neuromuscular function was monitored by a calibrated train-of-four (TOF) stimulation device. Paralysis time delay to reach TOF of 2/4, recovery kinetics and tolerance were monitored. The number needed to demonstrate a significant difference in time delays to reach a TOF of 2/4 between the two forms of cisatracurium was estimated at 22 patients. RESULTS: twenty-two patients were included. Eight (36.4%) had acute respiratory distress syndrome; 8(36.4%), acute exacerbation of chronic obstructive pulmonary disease and 3(13.6%), status asthmaticus. Median [IQR] SAPS II at admission, 28.5 [22, 41]. PaO2/FIO2, 121 [81, 156] mmHg. Paralysis time delays were respectively, 80 [50, 112] vs. 87 [65, 115] minutes, in Nimbex® group and Cisatrex® group; (p=0.579). Within the recovery period, the between two-studied drugs´ difference in TOF was at 0.25±0.96; p=0.64. There were no significant hemodynamic differences. CONCLUSION: the present study revealed no significant differences in efficacy nor in tolerance between cisatracurium brand name Nimbex® and generic name Cisatrex® in hypoxemic ventilated patients. The African Field Epidemiology Network 2020-12-15 /pmc/articles/PMC7934181/ /pubmed/33738034 http://dx.doi.org/10.11604/pamj.2020.37.346.24986 Text en Copyright: Nesrine Fraj et al. https://creativecommons.org/licenses/by/4.0 The Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Fraj, Nesrine Meddeb, Khaoula Azouzi, Abdelbaki Romdhani, Sana Saad, Helmi Ben Boussarsar, Mohamed Compared efficacy and tolerance of the neuromuscular blockade induced by brand-name (Nimbex®) and generic (Cisatrex®) of cisatracurium in mechanically ventilated critically ill patients: a crossover double-blind randomized study |
title | Compared efficacy and tolerance of the neuromuscular blockade induced by brand-name (Nimbex®) and generic (Cisatrex®) of cisatracurium in mechanically ventilated critically ill patients: a crossover double-blind randomized study |
title_full | Compared efficacy and tolerance of the neuromuscular blockade induced by brand-name (Nimbex®) and generic (Cisatrex®) of cisatracurium in mechanically ventilated critically ill patients: a crossover double-blind randomized study |
title_fullStr | Compared efficacy and tolerance of the neuromuscular blockade induced by brand-name (Nimbex®) and generic (Cisatrex®) of cisatracurium in mechanically ventilated critically ill patients: a crossover double-blind randomized study |
title_full_unstemmed | Compared efficacy and tolerance of the neuromuscular blockade induced by brand-name (Nimbex®) and generic (Cisatrex®) of cisatracurium in mechanically ventilated critically ill patients: a crossover double-blind randomized study |
title_short | Compared efficacy and tolerance of the neuromuscular blockade induced by brand-name (Nimbex®) and generic (Cisatrex®) of cisatracurium in mechanically ventilated critically ill patients: a crossover double-blind randomized study |
title_sort | compared efficacy and tolerance of the neuromuscular blockade induced by brand-name (nimbex®) and generic (cisatrex®) of cisatracurium in mechanically ventilated critically ill patients: a crossover double-blind randomized study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934181/ https://www.ncbi.nlm.nih.gov/pubmed/33738034 http://dx.doi.org/10.11604/pamj.2020.37.346.24986 |
work_keys_str_mv | AT frajnesrine comparedefficacyandtoleranceoftheneuromuscularblockadeinducedbybrandnamenimbexandgenericcisatrexofcisatracuriuminmechanicallyventilatedcriticallyillpatientsacrossoverdoubleblindrandomizedstudy AT meddebkhaoula comparedefficacyandtoleranceoftheneuromuscularblockadeinducedbybrandnamenimbexandgenericcisatrexofcisatracuriuminmechanicallyventilatedcriticallyillpatientsacrossoverdoubleblindrandomizedstudy AT azouziabdelbaki comparedefficacyandtoleranceoftheneuromuscularblockadeinducedbybrandnamenimbexandgenericcisatrexofcisatracuriuminmechanicallyventilatedcriticallyillpatientsacrossoverdoubleblindrandomizedstudy AT romdhanisana comparedefficacyandtoleranceoftheneuromuscularblockadeinducedbybrandnamenimbexandgenericcisatrexofcisatracuriuminmechanicallyventilatedcriticallyillpatientsacrossoverdoubleblindrandomizedstudy AT saadhelmiben comparedefficacyandtoleranceoftheneuromuscularblockadeinducedbybrandnamenimbexandgenericcisatrexofcisatracuriuminmechanicallyventilatedcriticallyillpatientsacrossoverdoubleblindrandomizedstudy AT boussarsarmohamed comparedefficacyandtoleranceoftheneuromuscularblockadeinducedbybrandnamenimbexandgenericcisatrexofcisatracuriuminmechanicallyventilatedcriticallyillpatientsacrossoverdoubleblindrandomizedstudy |